Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Tendonitis Treatment Market

Tendonitis Treatment Market Size

Report ID: GMI8326
Published Date: Feb 2024
Report Format: PDF

Download Free Sample

Tendonitis Treatment Market Size

Tendonitis Treatment Market size was valued at around USD 214.6 billion in 2023 and is anticipated to register a CAGR of 3.8% between 2024 and 2032. Tendonitis is a condition characterized by inflammation or irritation of a tendon. Tendons are fibrous tissues that connect muscles to bones, and when they become inflamed, it can result in pain, swelling, and discomfort in the affected area. Tendonitis often occurs due to overuse, repetitive motion, or strain on a particular tendon.

To get key market trends

Download Free Sample

Robust market growth can be attributed to various factors, including the rising prevalence of sedentary, lifestyles, the continual growth of healthcare expenditure, and ongoing technological advancements in tendonitis treatment. Additionally, a growing trend is observed towards an increasing preference for knee braces, which is estimated to reach USD 2.8 billion in 2032, among other contributing factors.

Furthermore, anticipated market expansion is attributed to multiple factors, including the rising incidence of cardiovascular, elderly population, sports and physical activities contributes to a higher incidence of tendonitis, especially among athletes. For instance, in 2022, according to National Safety Council Sports and recreational injuries increased by 12%.

Tendonitis Treatment Market Report Attributes
Report Attribute	Details
Base Year:	2023
Tendonitis Treatment Market Size in 2023:	USD 214.6 Billion
Forecast Period:	2024 – 2032
Forecast Period 2024 – 2032 CAGR:	3.8%
2024 – 2032 Value Projection:	USD 297.9 Billion
Historical Data for:	2018 – 2023
No. of Pages:	230
Tables, Charts & Figures:	394
Segments covered:	Treatment, Application, Distribution Channel, End-use, and Region
Growth Drivers:	Increasing prevalence of sports related injuries Rising incidence of bone related disorders Growing technological advancements Increasing awareness regarding physical fitness
Pitfalls & Challenges:	Inflated of cost of tendonitis treatment Lack of reimbursement scenario

Learn more about the key segments shaping this market

Download Free Sample

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Tendonitis treatment industry reached a revenue of USD 214.6 billion in 2023 and is estimated to cross USD 297.9 billion by 2032 attributed to the rising prevalence of sedentary, lifestyles, continual growth of healthcare expenditure, and the ongoing technological advancements.

The achilles tendonitis application segment is expected to generate USD 142.7 billion in revenue by the end of 2032 as it offers significant advantages to patients with effective relief without the need for surgery or invasive procedures.

North America tendonitis treatment industry size was USD 87 billion in 2023 and is set to expand at a notable CAGR through 2032 owing to the presence of sophisticated healthcare infrastructure, and an increased prevalence of tendonitis cases in the region.

Some of the major tendonitis treatment firms are Abbott Laboratories, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Bristol Myers Squibb Company, Colfax Corporation, GalxoSmithKline AG, Johnson & Johnson, Merck and Co., Inc., Ossur, Pifzer Inc., Stryker Corporation, Teva Pharmaceutical Industries Ltd., Tynor Orthotics Pvt. Ltd, and Zimmer Biomet Holdings, Inc.